Navigation Links
Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/10/2013

e adequate protection. In contrast, Inovio's vaccine is designed to broadly protect against multiple known and unknown strains within a subtype such as H1N1 – the unanswered question has been whether or not such a universal vaccine could broadly achieve protective levels of immune responses against unmatched flu strains and whether it could provide response rates (i.e. the number of subjects achieving protective immune response levels) equivalent to a conventional vaccine when tested against the virus strain matching that vaccine. This is the first demonstration of a SynCon® influenza vaccine achieving protective equivalency relative to a conventional seasonal vaccine while uniquely possessing the advantage of generating protective immune responses against diverse unmatched strains, which was also shown in this study as well as a prior study focused on H5N1.

Inovio and its partner VGX International, Inc. will move Inovio's hepatitis C (HCV) DNA vaccine into a phase I/IIa clinical trial by the end of 2013. The preclinical research, which demonstrated for the first time that a multi-antigen (NS3/4A, NS4B, and NS5A) SynCon® HCV vaccine can generate robust T-cell responses in the liver, an organ known to suppress T-cell activity, appeared in the peer-reviewed journal Plos One in an article entitled: "Induction of Intrahepatic HCV NS4B, NS5A and NS5B Specific Cellular Immune Responses following Peripheral Immunization." VGX International is funding all preclinical and clinical development.

Subsequent to the quarter, our collaborator ChronTech Pharma AB announced that preliminary results from their open label phase II clinical study of their ChronVac-C® (NS3/4A only) therapeutic HCV vaccine administered with Inovio's MedPulserTM-DDS electroporation device followed by a drug regimen (ribavirin + PEG-interferon-a) in chronic HCV positive subjects did not to date show a statistical
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
2. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
3. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
4. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
5. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
6. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
9. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
10. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
11. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... ITRA Global, one of the largest organizations dedicated ... has further expanded its global reach with the affiliation ... Australia, reports Mylinda Vick, CCIM, Chairman of the ITRA ... ACORPP (Australian Corporate Property and Projects) , is a ... to a wide range of clients in the private ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that its ... M1 in raw commingled milk is the first lateral ... peer reviewed report of the validation by Technology and ... Fisheries Research (ILVO-T&V) has been published by the Taylor ... toxic aflatoxin and a known carcinogen, can be passed ...
(Date:12/19/2014)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today ... privately held company based in Redwood ... big data platform for centralized management and processing ... on-market Genomic Management Solution, Bina-GMS 1 , empowers ... and scalable analyses to maximize the value of ...
(Date:12/19/2014)... DUBLIN , Dec. 19, 2014 Research ... announced the addition of the "Technology Innovations ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... Innovations in Smart Fabrics" offers a detailed assessment ... Key Findings: 1. ...
Breaking Biology Technology:ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Technology Innovations in Smart Fabrics (Technical Insights) 2
... New Service Helps Customers to Treat More Patients, ... ARAY ), a global leader in the ... begin offering a treatment planning,service to new and ... centers to access a dedicated team of remote ...
... Quintiles,Transnational Corp. today announced the completion of ... company,s continued,growth under the leadership of founder and ... management team. Gillings and global private,investment firms Bain ... in Quintiles, with 3i also becoming a significant ...
... Ind., Jan. 23 Zimmer Holdings, Inc.,(NYSE: ZMH ... announced,today it will be participating in the Wachovia Securities ... 10:15 a.m. Eastern Time., A live webcast of ... at http://investor.zimmer.com . The webcast will,be archived for ...
Cached Biology Technology:Accuray Announces New Treatment Planning Service Offering 2Accuray Announces New Treatment Planning Service Offering 3Accuray Announces New Treatment Planning Service Offering 4Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i 2Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i 3
(Date:12/10/2014)... DUBLIN , Dec. 08, 2014 Research ... announced the addition of the "Biometrics Market ... http://photos.prnewswire.com/prnh/20130307/600769 ... for projects such as rural banking and upgradation ... major trends witnessed in the market. Besides the ...
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... New York College, and one of the most prolific ... signals that are transmitted from Smartphones to third party ... Smartphones and has one of the earliest known patents ... its usage in the military, child care, elder care ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... Athens, Ga. Companion animals that have a long-term need ... top-selling antiplatelet drug marketed to humans: clopidogrel, commonly known ... Georgia College of Veterinary Medicine have found ,that clopidogrel may ... long-term anticoagulant therapy. In addition, it may offer a ...
... Associate Professor at The City College of New York (CCNY), have ... water so that it can be scooped up like the fat ... soup. The agent could potentially be used to recover oil lost ... Professor John said. In the laboratory, Professor John and colleagues ...
... in cities, disposing of garbage and recycling anything that ... city and cell, health problems can arise when the ... of Michigan cell biologist Haoxing Xu and colleagues reveals ... recycling center, the lysosome, functions. These insights, which may ...
Cached Biology News:Plavix may be treatment for dogs at risk of thromboembolic disease 2Opening the gate to the cell's recycling center 2